Drugs / EVX-02A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04455503 | Jul 2020 → Feb 2023 | metastatic melanoma | Evaxion Biotech A/S | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EVX-02A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04455503 ↗ |
| Route | Intramuscular | “EVX-02A administered IM.” NCT04455503 ↗ |